A small biotechnology rattles off its Covid-19 ‘one and done’ PhIII, prompting at least one top analyst to change its tune as stocks rise – Endpoints News
A small biotechnology rattles off its Covid-19 ‘one and done’ PhIII, prompting at least one top analyst to change its tune as stocks rise – Endpoints News

A small biotechnology rattles off its Covid-19 ‘one and done’ PhIII, prompting at least one top analyst to change its tune as stocks rise – Endpoints News

Is Merck ready to open a big new market for its PD-1 star?

That’s what the drug giant said when it released complete data from the Phase III KEYNOTE-091 study, which tested Keytruda against placebo as an adjuvant treatment for a group of patients with non-small cell lung cancer in phase IB-IIIA.

Keytruda, when given after surgical resection of the tumor, met the co-primary endpoint of disease-free survival regardless of PD-L1 expression, reducing the risk of disease recurrence or death by 24% (HR = 0.76, p = 0.0014 ). However, inexplicably, the second co-primary endpoint – which focuses on a subset of patients whose tumors express PD-L1, measured by tumor share score ≥50% – was not statistically significant (HR = 0.82, p = 0.14) .

Continue reading Endpoints with a free subscription

Unlock this story right away and join 136,300+ biopharma professionals who read Endpoints daily – and for free.


Leave a Reply

Your email address will not be published.